Albany, NY -- (ReleaseWire) -- 07/07/2014 -- Allergic Rhinitis is a chronic inflammatory disease of the nasal cavity which causes respiratory problems and affects all age groups. Common symptoms of the disease include sneezing, sore throat, nasal itching and blocked or running nose. The disease often goes unnoticed due to symptoms of the disease coincide with the symptoms of the common cold among humans. Allergic rhinitis can be of three types,such as, perennial, seasonal or both. The allergic rhinitis market can be classified into four major segments based on its treatment, namely, antihistamines, steroids, others and alternative treatment methods.
Browse the full report with request TOC at http://www.transparencymarketresearch.com/allergic-rhinitis-market.html
Major driving factors for the growth of allergic rhinitis market include, high prevalence of the disease, increasing respiratory disorders, increasing usage of tobacco and increasing demand for new and innovative treatments. According to the World Health Organization estimates, more than 400 million people suffered from allergic rhinitis from 1996 to 2006. The disease can also be highly potent due to negligence, as many a times it goes unnoticed and improper treatment methods may be adopted. Various researches are going around the world to bring new drugs which will help in improved treatments of the disease. These factors will drive the growth of this market in future.
Buy This Report with 10% Discount and Customize as per Your Requirement @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2126
Geographically, North America is the largest market with the U.S. having highest prevalence of allergic rhinitis disease, followed by the European market. Asia-Pacificis the fastest growing market with increasing prevalence of the disease and increasing awareness about the disease and its treatments, of the population in the region. Globally, Japan has the second highest prevalence of the disease after the U.S. Some of the important players operating in this market are Alcon, Inc., Array BioPharma, Inc., Dainippon Sumitomo Pharma Co., Ltd., Genentech, Inc., GlaxoSmithKline plc, Hisamitsu Pharmaceutical Co., Inc., Nektar Therapeutics, Novartis AG, Revance Therapeutics, Inc., Shionogi & Co., Ltd., and Stallergenes S.A.
90 State Street,
Albany NY - 12207